- Once-weekly treatment with polyethylene glycol loxenatide (PEX168), a new long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, was associated with significant reductions in HbA1c compared with placebo in patients with type 2 diabetes (T2D) uncontrolled by metformin alone.
Why this matters
- Metformin monotherapy may not adequately control glycemia in patients with T2D.
- Patients with uncontrolled T2D (HbA1c, 7.0%-10.5%) were randomly assigned:
- Metformin plus placebo (n=179).
- Metformin plus PEX168 100 μg (n=179).
- Metformin plus PEX168 200 μg (n=175).
- The treatment period lasted 24 weeks, followed by a 28-week extension phase.
- Primary outcome was change in HbA1c at the end of the 24-week treatment period.
- Funding: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- Significant reductions in HbA1c from baseline to week 24 were observed in the PEX168 100 µg (1.16%±1.11%, P<.001 and pex168 p groups.>
- At week 24, a higher proportion of patients who achieved an HbA1c
- Researchers observed sustained reductions in HbA1c to week 52 with PEX168 100 µg (8.5%±0.89% to 7.7%±1.15%, P<.001 and pex168 to p>
- Mild gastrointestinal events were reported.
- Relatively short follow-up duration.